Empagliflozin Cuts Cardiovascular Deaths in Advanced Heart Failure

Patients treated for advanced but stable heart failure, including those with diabetes, had a 25% lower risk of cardiovascular death or hospitalization for heart failure when they received empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, according to an international trial in the New England Journal of Medicine.
Source: JAMA - Category: General Medicine Source Type: research